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Background: Holt-Oram syndrome (HOS) is an autosomal dominant disorder characterised by upper limb
anomalies and congenital heart defects. We present epidemiological and clinical aspects of HOS patients using data
from EUROCAT (European Surveillance of Congenital Anomalies) registries.
Methods: The study was based on data collected during 1990–2011 by 34 registries. The registries are population-
based and use multiple sources of information to collect data on all types of birth using standardized definitions,
methodology and coding. Diagnostic criteria for inclusion in the study were the presence of radial ray abnormalities
and congenital heart disease (CHD), or the presence of either radial ray anomaly or CHD, with family history of HOS.
Results: A total of 73 cases of HOS were identified, including 11 (15.1%) TOPFA and 62 (84.9%) LB. Out of 73 HOS
cases, 30.8% (20/65) were suspected prenatally, 55.4% (36/65) at birth, 10.7% (7/65) in the first week of life, and 3.1%
(2/65) in the first year of life. The prenatal detection rate was 39.2% (20/51), with no significant change over the
study period. In 55% (11/20) of prenatally detected cases, parents decided to terminate pregnancy. Thumb
anomalies were reported in all cases. Agenesis/hypoplasia of radius was present in 49.2% (30/61), ulnar aplasia/
hypoplasia in 24.6% (15/61) and humerus hypoplasia/phocomelia in 42.6% (26/61) of patients. Congenital heart
defects (CHD) were recorded in 78.7% (48/61) of patients. Isolated septal defects were present in 54.2 (26/48), while
25% (12/48) of patients had complex/severe CHD. The mean prevalence of HOS diagnosed prenatally or in the early
years of life in European registries was 0.7 per 100,000 births or 1:135,615 births.
Conclusions: HOS is a rare genetic condition showing regional variation in its prevalence. It is often missed
prenatally, in spite of the existence of major structural anomalies. When discovered, parents in 45% (9/20) of cases
opt for the continuation of pregnancy. Although a quarter of patients have severe CHD, the overall first week
survival is very good, which is important information for counselling purposes.
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Holt-Oram syndrome (HOS, OMIM 142900) is a rare
autosomal dominant multiple malformation syndrome
characterised by high penetrance and variable expression
of upper limb abnormalities, congenital heart defects
(CHD) and/or conduction abnormalities [1,2].
Sequence variants of TBX5 gene, a member of the
T-box family of transcription factors, have been iden-
tified to affect function in 75% of HOS cases [3-5].
Most are truncating alterations that result in haploin-
sufficiency, but occasionally sequence variations can
lead to extension of the TBX5 protein [6,7]. Different
types of sequence variants can cause complete loss or
reduction of TBX5 protein function by affecting nuclear
localisation of the protein or by disrupting its inter-
action with other transcriptional cofactors and down-
stream target genes. Some sequence variants may result
in the gain-of-function causing a similar phenotype
[8-13]. Since under- and overexpression cause the same
phenotype, TBX5 function is considered to be gene dos-
age sensitive [13].
The carriers of the TBX5 allelic variants affecting func-
tion show high intra- and interfamilial variability of cli-
nical presentation. These variations can be due to the
type and location of the sequence alteration, but also to
other modifier factors, e.g., sequence variations in en-
hancers regulating TBX5 expression during heart devel-
opment [14].
Clinical diagnostic criteria of HOS include pre-axial
radial ray malformations in at least one upper limb and
CHD and/or conduction defects [15,16]. When a heart
anomaly is not present, there should be a family history
of HOS consistent with an autosomal dominant type of
inheritance [2,5,15]. The spectrum of skeletal upper limb
defects ranges from an abnormal carpal bone or tripha-
langeal/fingerlike thumb to bilateral phocomelia. CHD is
present in 75% of individuals with HOS. Ostium secun-
dum atrial septal defect (ASD) and ventricular septal de-
fect (VSD) are the most common, but other more severe
heart anomalies have been reported as well [2,17]. Con-
duction heart disease may occur in the absence of struc-
tural anomaly. No correlation between the severity of
heart and limb defects has been established.
Several large clinical series of HOS patients have been
published examining the clinical presentation, diffe-
rential diagnosis and diagnostic criteria [16,18,19], but
population-based epidemiological studies are rare be-
cause of the need for large populations and standardised
data collection. The prevalence of HOS is estimated to be
0.95/100,000 births, based on a single epidemiological
study from Hungary [20]. Most clinical reports refer to
live born (LB), children or adults, while there is little infor-
mation on fetal deaths (FD), terminations of pregnancy
after prenatal ultrasound detection of severe anomaly/anomalies (TOPFA) and on patients diagnosed in the
neonatal period.
The aim of this study was to investigate the epidemio-
logical and clinical aspects of HOS patients diagnosed
prenatally or in the early years of life, using data notified
to the European Surveillance of Congenital Anomalies
(EUROCAT) database.
Methods
The study was based on data routinely collected in the
period from 1990 to 2011 by 34 EUROCAT registries in
16 countries covering approximately 30% of Europe's
annual birth population and extracted from the central
database in June 2013. The EUROCAT registries are
population-based and use multiple sources of information
to collect data on all major structural congenital anomal-
ies, chromosomal abnormalities, and other genetic and
environmental conditions presenting with structural de-
fects among LB, FD with gestational age (GA) ≥20 weeks,
and TOPFA using standardized definitions and coding.
Six registries include cases diagnosed up to one week
after birth, three up to one month, and 25 registries in-
clude cases diagnosed up to at least one year of age. A
detailed description of registries, methods of case ascer-
tainment, data collection and processing is available
elsewhere [21,22].
The central EUROCAT database was searched for
the International Classification of Diseases (ICD)/British
Paediatric Association (BPA) version 9 (759.842, 759.84),
ICD10/BPA (Q87.20) and OMIM (142900) codes as-
signed to cases of HOS. Diagnostic criteria for inclusion
in the study were the presence of radial ray abnormalities
and CHD, or the presence of either radial ray anomaly or
CHD, with family history of HOS [2,4]. Minor anomalies,
including those detectable exclusively by x-ray (e.g., carpal
bone defects, hypoplasia of hand/arm/shoulder muscles,
sloping shoulders), functional limb defects (e.g., minor
limitation of movements of thumbs, elbows, or shoulders)
or heart defects (e.g., conduction abnormalities) were not
systematically recorded, as the EUROCAT focus is on col-
lecting data on major structural anomalies [21].
In two-thirds of EUROCAT registries, clinical geneti-
cists take part in the examination and diagnosing of all
patients with dysmorphic features and congenital ano-
malies, and in the remaining registries clinical gene-
ticists participate in the examination of selected cases
[23]. This genetic expertise allows EUROCAT to collect
and analyse data on rare genetic syndromes that mani-
fest a characteristic pattern of anomalies prenatally, at
birth or in early infancy [23-25]. A medical geneticist
reviewed all records including textual description in
order to include all relevant clinical information. Local
registries were contacted to provide additional/missing
information.
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diagnosis (pre- or postnatal), birth outcome (proportion
of LB, FD at GA ≥20 weeks, TOPFA), type of congenital
anomalies (ICD9/ ICD10 code and written text), infant
sex, survival up to 1 week of age, maternal and paternal
age at delivery, birth weight (BW), GA at birth or termin-
ation of pregnancy, use of assisted reproductive tech-
niques (ART), multiple pregnancy (twin or triplet), and
family history. Until very recently, data on genetic testing
were not systematically collected and therefore were not
included in this study.
Statistics
Descriptive data are presented as numbers and percent-
ages for categorical data. Means and 95% confidence in-
tervals, based on Poisson distribution, were used to
calculate prevalence and a Generalized Linear/Nonlinear
model based on Poisson distribution was used for statis-
tical testing of time trends. A difference between two
proportions test was used to test prevalence differences
between registries and the total prevalence rate. A chi-
square test was performed to determine differences in
maternal age distribution between HOS and other
EUROCAT cases. Maternal age comparisons were re-
stricted to the registries/time period with available ma-
ternal age denominator data (63% of EUROCAT total
birth population). Statistical analysis was performed
using STATISTICA 6.1 StatSoft Inc. 1983–2003 (serial
number AGA304B211928E61).
Results
Between January 1990 and December 2011, a total of 73
cases of HOS were identified in the European population
covered by 34 European registries included in the
EUROCAT network. There were 11 (15.1%) TOPFA, no
FD, and 62 (84.9%) LB. Two of the 62 LB children died
in the neonatal period (3.2%). Among the patients for
which the time of diagnosis was known (n = 65), 30.8%
were diagnosed prenatally, 55.4% at birth, 10.7% in the
first week of life, and 3.1% in the first year of life.
The prenatal detection rate was 39.2% (20/51) with no
significant change between the 1990–2000 and 2001–
2011 periods (P > 0.05) (Table 1). The mean GA at pre-
natal diagnosis by obstetric ultrasound was 18.6 ± 4.6
(range 14–26) gestational weeks. In 55% (11/20) of casesTable 1 Outcome of pregnancies and prenatal detection of H
Monitored period Total no. of patients LB FD TOPFA
1990-2000 42 38 0 4
2001-2011 31 24 0 7
1990-2011 73 62 0 11
Abbreviations: LB live born, FD fetal deaths, TOPFA termination of pregnancy for fetawith prenatally diagnosed severe anomaly/anomalies,
parents decided to terminate the pregnancy. The mean
GA at termination was 21.1 ± 1.8 (range 14–35) gesta-
tional weeks. The diagnosis was verified by post mortem
examination in 10 of 13 cases (eight TOPFA and two
neonatal deaths). In 31 out of 51 cases with available
data (60.8%), prenatal ultrasound was performed but did
not detect any anomaly, although major anomalies (e.g.,
absence of forearm, bilateral radial aplasia, tetralogy of
Fallot, pentalogy of Fallot, etc.) were present in 10/31
patients detected postnatally. Three undetected cases
were familial.
Characteristics of the HOS patients are shown in
Table 2. The male-to-female ratio was 1.1:1. The mean
GA in LB was 39.3 ± 3.1 (range 33–42) in males and
38.4 ± 2.9 (range 27–42) in females. The mean BW was
2998 ± 370 g (range 2240–3800 g) for males and 3241 ±
458 g (range 2400–4200 g) for females. Of 62 live born
cases, 96.8% survived the first week of life.
Eleven families had more than one affected member.
Maternal age distribution did not differ significantly
from that of the total EUROCAT population (P = 0.06).
Multiple pregnancies were not noted. Three of 34 pa-
tients with known information on ART were conceived
by induced ovulation. There were no cases of in vitro
fertilization (IVF) or intracytoplasmic sperm injection
(ICSI). Data on karyotyping were available for 46.1% of
cases and all results were normal.
Description of the type and frequency of major con-
genital anomalies was available for 61 HOS patients. The
results are presented in Table 3, together with those on
the three large series of HOS patients published so far.
Thumb anomalies were present in all patients. Agenesis/
hypoplasia of radius was present in 49.2% (30/61), ulnar
aplasia/hypoplasia in 24.6% (15/61), and humerus hypo-
plasia/phocomelia in 26/61 (42.6%) patients.
CHD was recorded in 78.7% (48/61) of patients. Iso-
lated septal defects were present in 54.2%, ASD + VSD
in 8.3% and various other CHD in 12.5% of cases
(Table 4). There were 25% of patients with complex/
severe heart defects: tetralogy of Fallot (1), pentalogy of
Fallot (1), pulmonary valve atresia (1), atrial septal defect
and tricuspid atresia (1), VSD and tricuspid atresia (1),
AVSD with multiple ventricular septal defects (2), AVSD
with multiple ASD (1), common arterial truncus (1),olt Oram syndrome in the EUROCAT registries, 1990-2011
Prenatally detected/number of
patients with available data
Prenatal detection rate% (95% CI)
11/28 39.3 (95% CI 21.2-57.4)
9/23 39.1 (95% CI 19.2-59.1)
20/51 39.2 (95% CI 25.8-52.6)
l anomaly, 95% CI 95% Confidence Interval.
Table 2 Descriptive epidemiological data on patients
with Holt Oram syndrome, EUROCAT registries,
1990-2011
Characteristics Number of HOS patients N = 73 (%)
Sex
Male 38 (52.8)
Female 34 (47.2)
Unknown 1
Gestational age, wk N = 59
(live births with known gestational
age and sex)
M F
n = 27 n = 32
<37 5 (18.5) 4 (12.5)
37-41 20 (74.1) 25 (78.1)
≥42 2 (7.4) 3 (9.4)
Birth weight (g) N = 47
(live births with known gestational
weight and sex)
M F
N = 20 N = 27
<1500 0 0
1500-1999 3 (15.0) 1 (3.7)
2000-2499 6 (30.0) 8 (29.6)
2500-2999 10 (50.0) 10 (37.1)
3000-3499 1 (5.0) 7 (25.9)
>3500 0 1 (3.7)
Positive family history 15.1% (11/73)
Mean maternal age (range) 28.3 ± 4.6 (17–41)
Mean paternal age (range) 32.7 ± 1.3 (19–62)
wk: weeks.
g: grams.
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ASD and VSD (1), and double outlet right ventricle
(DORV) (1).
CHD was present in all but one familial case (90%). In
this maternal case, there was aplasia of the thumb and
radial hypoplasia without CHD. Distribution of CHD
types among familial and sporadic cases is shown in
Table 4.
The prevalence of HOS was restricted to data from 16
registries with an above average prevalence of genetic
syndromes and microdeletions (EUROCAT average is
4.8 per 10,000 births) according to the Data Quality In-
dicators developed by EUROCAT (http://www.eurocat-
network.eu/content/DQI-2013.pdf ). This was done in
order to ensure a more homogeneous ascertainment of
cases. During the 1990–2011 period, a total population
of 5,017,781 births were monitored in these registries
and 37 cases of HOS identified. Therefore, the meanprevalence of HOS diagnosed in the early years of life
was 0.7 per 100,000 births or 1: 135,615 births. The
prevalence rates for 1990–2000 and 2001–2011 were 1.1
and 0.4 per 100,000 births, respectively (P = 0.03) (Table 5).
The number of HOS patients and prevalence rates per
registry are shown in Table 6.
Discussion
The Holt-Oram syndrome is an autosomal dominant
condition associated with defective development of the
radial ray and cardiac structures, resulting in a wide
spectrum of phenotypes. It needs to be emphasized that
there is no intellectual impairment which is important
information for genetic counselling of affected families.
The diagnosis is based on established clinical criteria
and can be confirmed by molecular genetic testing in a
proportion of cases. The diagnosis is not difficult in the
presence of typical clinical features and positive family
history. In isolated cases, the differential diagnosis will
include hand-heart syndromes type II (Tabatznik) and
III (Spanish type), other genetic syndromes with upper
limb anomalies (e.g., thrombocytopenia-absent radius
syndrome, Fanconi anaemia, SALL4-related disorders,
ulnar mammary, Kaufmann McKusick, Roberts or Nager
syndromes), chromosomal anomalies, associations such
as VACTERL and rare teratogenic embryopathies (thal-
idomide, valproate) [2,26]. In most cases, these condi-
tions can be excluded without major difficulties by
careful clinical examination and appropriate diagnostic
evaluation including cytogenetic and molecular testing.
These tests, including genetic testing for TBX5, 22q11.2
microdeletion and Fanconi anaemia, were also per-
formed in the studied patients as a part of the routine
clinical evaluation for establishing the final diagnosis.
We are not able to present these data, as we have only
recently started to collect data on genetic testing in a
systematic way.
Prenatal diagnosis
As HOS is rare and most cases are sporadic, it is mostly
reported in familial cases when a more detailed ultra-
sound examination is performed rather than by prenatal
screening [27,28]. The radius and ulna are easy to see at
13–16 weeks, and most cardiac anomalies, with excep-
tion of ASD and small VSD, are clearly visible on ultra-
sound screening for anomalies at 18–20 weeks. Our
study showed that over 60% of cases were not suspected
prenatally, although many presented with major anomal-
ies that could have been easily detected by prenatal
ultrasound and although some cases were familial. In
addition, the prenatal detection rate did not improve
over time.
Parents of the 9 of 20 patients diagnosed prenatally
decided to continue the pregnancy. Two cases were
Table 3 Major congenital anomalies in Holt Oram syndrome: EUROCAT data and in previously published studies
TYPE OF ANOMALY EUROCAT STUDY Newbury-Ecob et al.,
1996 [16]
Hurst et al.,
1991 [19]
Smith et al.,
1979 [18]
N = 61 (%) N = 55 (%) N = 43 (%) N = 39 (%)
Congenital heart anomalies*
Atrial septal defect 28 (45.9) 20 (36.4) 20 (46.5) 14 (35.9)
Ventricular septal defect 23 (37.7) 15 (27.2) 3 (7.0) 9 (23.1)
Atrioventricular septal defect 3 (4.9) 1 (2.6)
Pulmonary atresia/stenosis 2 (3.3) 1 (1.8) 1 (2.6)
Double outlet right ventricle 1 (1.6) 1 (2.6)
Aortic valve insufficiency 1 (1.6) 1 (2.6)
Aortic valve stenosis 2 (3.6)
TrIcuspid atresia 2 (3.3)
Mitral valve abnormality 3 (5.5) 1 (2.3) 2 (5.1)
Patent ductus arteriosus 3 (4.9) 1 (1.8) 1 (2.3) 1 (2.6)
Pentalogy of Fallot 1 (1.6)
Tetralogy of Fallot 1 (1.6) 2 (3.6)
Common arterial truncus 1 (1.6)
Dextrocardia 1 (1.6) 1 (1.8) 1 (2.3) 1 (2.6)
Right aortic arch 1 (2.6)
Congenital heart disease, NOS 1 (1.6) 4 (10.3)
LIMBS
Thumbs
Triphalangeal/digital thumb 24 (39.3) 10 (18.2) 10 (23.3) 24 (61.5)
Hypoplasia of thumb 16 (26.2) 21 (38.2) 9 (20.9) 13 (33.3)
Absence of thumb 30 (49.1) 27 (49.1) 10 (23.3) 16 (41.0)
Accessory/bifid thumb 4 (6.6) 1 (2.6)
Syndactyly of thumb 3 (4.9) 7 (12.7) 6 (15.4)
Fingers
Aplasia of hand and/or fingers 8 (13.1) 6 (10.9) 8 (20.5)
Hypoplasia of hand and/or fingers 8 (13.1) 7 (12.7) 8 (20.5)
Syndactyly 20 (32.8) 6 (10.9) 16 (41.0)
Lower arm
Agenesis radius 14 (23.0) 13 (23.6) 8 (20.5)
Hypoplastic radii, short forearms 16 (26.2) 24 (43.6) 9 (20.9) 12 (30.8)
Ulnar hypoplasia 11 (18.0) 20 (36.4) 7 (17.9)
Ulnar aplasia 4 (6.6) 4 (7.3) 1 (2.6)
Synostosis of radius and ulna 12 (19.7) 32 (58.1) 5 (12.8)
Upper arm
Humerus hypoplasia 24 (39.3) 28 (50.9) 10 (25.6)
Humerus aplasia/Phocomelia 2 (3.3) 1 (1.8) 3 (7.0) 1 (2.6)
Clavicles, abnormalities 8 (13.1) 40 (72.2) 11 (28.2)
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Table 3 Major congenital anomalies in Holt Oram syndrome: EUROCAT data and in previously published studies
(Continued)
THORAX
Rib anomalies 2 (3.3) 5 (12.8)
SPINE
Hemivertebra 1 (1.6) 1 (2.6)
Fusion of vertebrae 1 (2.6)
*Congenital heart anomalies are presented per type of anomaly and not per patient.
NOS = non specified.
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the remaining seven, there were three familial cases sug-
gesting that families accept and tolerate well the clinical
consequences of the genetic disorder in their family, as
there is no intellectual impairment.
Clinical manifestations
The distribution of gender was equal. The intrauterine
growth and development was not affected. Over two-
thirds of HOS patients were born at term and of 50 pa-
tients born after 37 weeks of gestation, only four (8%)
weighed less than 2,500 g. Likewise, the first week sur-
vival was excellent, taking into account a high rate of se-
vere congenital heart anomalies.
By definition, all HOS patients have upper extremity
anomalies. Bone abnormalities are usually bilateral and
asymmetric, with left side often more affected than the
right side. Most skeletal manifestations are visible on in-
spection but some patients have only functional abnor-
malities or carpal/metacarpal bone anomalies visible on
x-ray. These functional and subclinical skeletal manifes-
tations of HOS were not systematically reported in our
dataset, as EUROCAT records major anomalies, while
recording of minor anomalies and functional symptoms
is optional and would be included in the database only if
associated with a major defect. In addition, some of
these manifestations are difficult to assess prenatally, at
post mortem, or in the neonatal period/infancy, when
most of our patients were diagnosed.Table 4 Type of congenital heart defect in sporadic and
familial patients with Holt Oram syndrome (N = 48)
Type of CHD Sporadic Familial TOTAL
ASD 13 (34.2%) 5 (50.0%) 18 (37.5%)
VSD 7 (18.4%) 1 (10.0%) 8 (16.7%)
ASD + VSD 2 (5.3%) 2 (20.0%) 4 (8.3%)
Complex 12 (31.6%) - 12 (25%)
Other 4 (10.5%) 2 (20.0%) 6 (12.5%)
TOTAL 38 10 48/61* (78.7%)
*Number of HOS patients with available data on type and frequency of major
congenital anomalies.
CHD - congenital heart defect, ASD - atrial septal defect, VSD - ventricular
septal defect.The most common thumb anomalies were absence of
thumbs, followed by triphalangeal/digital thumbs and
thumb hypoplasia. Radial hypoplasia was only slightly
more common than radial agenesis. The involvement of
the ulna was less frequent than of the radius. Upper arm
involvement was present in over 40% of patients. These
findings are largely in agreement with previous clinical
reports [16,18,19]. Due to the previously mentioned
methodology issues, synostosis of radius and ulna and
subtle shoulder anomalies (narrow shoulders, short clav-
icles/hypoplasia of head of humerus, and hypoplastic
musculature of the shoulder girdle) are probably under-
reported. Contrary to the observation of Newbury Ecob
et al. [16], no difference between isolated and familial
cases in the severity of thumb aplasia, radial and ulnar
involvement was observed. The predominant ulnar in-
volvement and atypical findings in isolated cases were
not noted. Only 1 in 30 patients had phocomelia, which
is somewhat less than previously observed [16,29]. Smith
et al. [18] found phocomelia to be present more often in
familial cases and in females. Both cases of phocomelia
found in our series were recorded in males and were
sporadic. Some studies noted that skeletal defects were
more severe in females than in males [18,29-31], but that
males had a greater number of bones involved than fe-
males [18]. In this study, we did not observe any sex dif-
ference in the type and number of skeletal defects.
CHD occur in approximately 75% of HOS patients. A
variety of structural heart anomalies are seen, with ASD
and VSD being the most common. The proportion of
CHD found in this study was 78.7%. In particular, we
observed a higher rate of VSD and a higher rate ofTable 5 Prevalence of Holt Oram syndrome patients in 16
selected EUROCAT registries, 1990-2011
Monitored
period
Total
births
Total no.
of patients
Birth prevalence
per100 000 (95% CI)
1990-2000 2 387 019 26 1.1 (0.69-1.51)
2001-2011 2 630 762 11 0.4 (0.2-0.6)
1990-2011 5 017 781 37 0.7 (0.32-1.08)
Abbreviations: 95% CI, 95% Confidence Interval.
Note: the registries were selected according to the http://www.eurocat-
network.eu/content/DQI-2013.pdf.
Table 6 Prevalence of Holt Oram syndrome patients per
16 selected EUROCAT registries, 1990–2011
REGISTRY Population No. of HOS
patients
(confirmed
familial cases)
Prevalence
per 100000
Styria (Austria) 229506 2 (2) 0.9
Antwerp (Belgium) 341573 2 0.6
Hainaut (Belgium) 277204 4 (2) 1.4
Dublin (Ireland) 489614 1 0.2
Odense (Denmark) 121532 1 0.8
Paris (France) 703650 3 0.4
Mainz (Germany) 75496 1 1.3
Cork And Kerry (Ireland) 141421 1 0.7
N Netherlands (Nl) 421026 7 (2) 1.7*
Vaud (Switzerland) 166950 4 (1) 2.4*
Glasgow (UK) 122803 1 0.8
N W Thames (UK) 661527 2 0.3
Wessex (UK) 492559 5 1.0
Thames Valley (UK) 291759 1 (1) 0.3
Northern England (UK) 382900 1 0.3
Malta 98261 1 (1) 1.0
TOTAL 5017781 37 0.7
*Registries with statistically significantly higher prevalence rates compared to
the total average prevalence rate (P < 0.05).
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of patients included a more severely affected subset of
patients compared with the clinical series that describe
mostly adult patients coming from affected families.
HOS patients in our study were diagnosed mostly at
birth or prenatally, and pregnancies with severe CHD
that resulted in TOPFA were also included. Additionally,
some of the VSDs diagnosed at birth would eventually
resolve and will not be recorded later in childhood or in
adulthood. Although the number of familial cases in our
series is small, it is of note that none of them had com-
plex CHD.
Cardiac conduction abnormalities are commonly found
in HOS. They are more likely to occur in those with a
structural heart defect, but it is reported that about 40%
of cases have conduction abnormalities alone [16]. We
were not able to study this manifestation of HOS, as re-
cording of functional abnormalities is optional and re-
ported data are not complete. It is therefore possible
that some patients with upper limb anomalies and only
conduction heart defects will be diagnosed later in ado-
lescence or adulthood when the symptoms of heart dis-
ease develop.
Other associated anomalies have also been described
in HOS patients and may include craniofacial, tracheal,
pulmonary, vertebral, renal and lower limb anomalies[5,32-36]. These can be incidental findings or may be
atypical cases of HOS due to specific sequence variants
of the TBX5 gene [11,36,37]. We observed single cases
with cleft uvula, brain cyst, spleen anomaly, pyelon duplex,
ectopic kidney and hemivertrebra. Lower limb anomalies
were found in 3 patients. The types of anomalies (one
bilateral hip dislocation, one lower limb shortening, one
club foot) would suggest random association rather than
the clinical spectrum of HOS.
Two cases with renal anomalies and a case with hemi-
vertebra were evaluated for the possible diagnosis of
VATER, but this was not conclusive. The patient with
hemivertebra had ASD type secundum, radial and
thumb aplasia on the right hand and phocomelia on the
left side, which is more indicative of HOS. Data on mo-
lecular tests for cases with associated anomalies were
not available.
The proportion of familial cases was 15.1%, which is
consistent with the results of the only population study
on HOS [20] and contrasts with clinical reports citing
that up to 85% of cases are familial due to the ascertain-
ment bias [16,20,23]. The mean parental age did not dif-
fer from the general EUROCAT population, although a
wide range (19–62 years) of paternal ages was observed.
ART methods are known to be associated with a higher
risk of congenital anomalies, especially congenital heart
defects [38,39] and are a risk factor for some genetic
syndromes [25,40]. In addition, ART could facilitate
propagation of pre-existing mutations that are associ-
ated with impaired fertility, e.g., in the sperm of older
men [41]. Our sample, although small, did not show
correlation between the ART techniques and HOS.
Prevalence
The results of this European study show that HOS is a
very rare condition with an average prevalence of 0.7 per
100,000 births and a high regional variation [range 0.3
(N W Thames)-2.4 (Vaud) or 1: 330,763 to 1: 41,737].
The prevalence is higher in registries were familial cases
are recorded. The mean prevalence of 1: 135,615 births
represents a minimum figure and refers to a group of
patients with obvious clinical presentation.
The only population-based study on HOS was con-
ducted in Hungary covering the 1975–1988 period [20].
The established prevalence of 0.95 per 100,000 births is
in agreement with the prevalence of 1.0 per 100,000
births recorded in our dataset for 1990–2000. Interest-
ingly, there is a significant decrease in the prevalence
rate for 2001–2011 period, for which there is no obvious
explanation and requires further monitoring.
Strengths and limitations of the study
This is the largest population-based study on HOS to
date. The results are based on the same methodology
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pertise to have confidence in the clinical diagnosis. All
cases met strict diagnostic criteria as proposed by
McDermott [2005, 2013], but a proportion of mild cases
without overt anomalies within the radial ray or those
with only conduction heart defects are missed. Another
study limitation is that we have data on genetic testing
only for a minority of patients, which does not allow
genotype phenotype analysis or confirmation of cases
with associated anomalies.
Conclusions
HOS is a rare genetic condition with regional variability.
It is often missed prenatally in spite of the presence of
major anomalies. When discovered, half of the parents
will opt to continue the pregnancy even in the presence
of severe limb defects and CHD. Our data indicate that
the number of severe CHD in HOS is underestimated
since they are present in one quarter of HOS patients. In
spite of this, the overall first week survival is good,
which is important information for genetic counselling
of affected families.
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